Incanthera PLC Issue of Equity (8169A)
27 Septembre 2022 - 9:17AM
UK Regulatory
TIDMINC
RNS Number : 8169A
Incanthera PLC
27 September 2022
27 September 2022
Incanthera plc
("Incanthera" or the "Company")
Issue of Equity
Incanthera plc (AQSE: INC), the specialist oncology company
focused on innovative technologies in dermatology and oncology
announces that it has issued 2,302,157 ordinary shares in the
Company ("New Ordinary Shares") at a price of 6.95 pence per share
to service providers in lieu of contractual amounts owed.
Furthermore, the Company has issued 1,079,136 warrants over
ordinary shares, with an exercise price of 6.95 pence per share and
an exercise period of five years from the date of issue.
It is expected that admission of the shares will become
effective at 8.00 a.m. on or around 3 October 2022.
Following admission of the New Ordinary Shares, the Company's
enlarged issued share capital will comprise 76,385,028 ordinary
shares of 2 pence each. This figure may be used by shareholders in
the Company as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in the interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018 ).
The directors of the Company take responsibility for this
announcement.
For further enquiries:
Incanthera plc:
+44 (0) 7831
675747
www.incanthera.com
Tim McCarthy, Chairman +44 (0) 7747
tim.mccarthy@incanthera.com 625506
Simon Ward, Chief Executive Officer simon.ward@incanthera.com
+44 (0) 7776
Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP +44 (0) 20
Jo Turner/James Lewis 7213 0880
Broker:
Stanford Capital Partners Ltd +44 (0) 20
Patrick Claridge/Tom Price/John Howes/Bob Pountney 3815 8880
Notes to Editors
Incanthera is dedicated to innovative technologies in
dermatology and oncology. It seeks to identify and commercialise
inspirational therapeutics combined with uniquely targeted delivery
systems, for innovative solutions to clinical, commercially
relevant unmet needs.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. The Company is
currently focussed upon delivering Sol to a commercial partner.
Originating from the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford, the Company has acquired and developed
a portfolio of specific cancer-targeting therapeutics, with a
strategy to develop each candidate from initial
acquisition/discovery to commercially valuable partnerships at the
earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXLRMRTMTBTMFT
(END) Dow Jones Newswires
September 27, 2022 03:17 ET (07:17 GMT)
Incanthera (AQSE:INC)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Incanthera (AQSE:INC)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
